The Effect of Empagliflozin Versus Metformin on Hormonal, Metabolic and Cardiovascular Risk Factors in Patients With Polycystic Ovary Syndrome (PCOS) - a Randomised Open-label Parallel Study.

Trial Profile

The Effect of Empagliflozin Versus Metformin on Hormonal, Metabolic and Cardiovascular Risk Factors in Patients With Polycystic Ovary Syndrome (PCOS) - a Randomised Open-label Parallel Study.

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Empagliflozin (Primary) ; Metformin
  • Indications Polycystic ovary syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Sep 2017 Status changed from not yet recruiting to recruiting.
    • 22 Jul 2017 Planned initiation date changed from 1 Jun 2017 to 1 Aug 2017.
    • 23 Mar 2017 Planned End Date changed from 1 Mar 2018 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top